Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.84 +5.07%

+$2.47 today

Market cap
$117.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.06M

Average 0.06M

SPRB EBITDA Margin

EBITDA as a percentage of revenue.

Spruce Biosciences, Inc.NASDAQ: SPRB

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
-1072.8%
Year-over-year change
-603.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SPRB compares with its peers on the latest reported figures

SPRB Competitors Peer median
EBITDA Margin for SPRB and competitors
Company Period LTM level YoY 3-year change
VTVTvTv Therapeutics Inc.LTM Mar 2026-1.9% +134274.5 pp—
CUECue Biopharma, Inc.LTM Mar 2026-48.4% +416.8 pp+3974.4 pp
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-104.8% ——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-769.0% +15034.6 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1017.5% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
EQEquillium, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
Peer median (excluding SPRB) -436.9%+7725.7 pp+3974.4 pp

Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0010.09M4.91M0
Cost of Revenue00000
Gross Profit0010.09M4.91M0
Gross Margin——100.0%100.0%—
Research & Development30.7M35.2M49.43M46.42M19.52M
Selling, General & Admin11.37M12.09M12.65M14.64M16.99M
Operating Expenses42.07M47.28M62.08M61.06M36.51M
Depreciation & Amortization68K74K70K46K21K
EBITDA(41.88M)(45.69M)(47.37M)(52.68M)(38.86M)
EBITDA Margin——-469.5%-1072.8%—
Operating Income(42.07M)(47.28M)(51.99M)(56.15M)(36.51M)
Operating Margin——-515.3%-1143.4%—
Interest Income119K1.52M4.56M3.42M1.14M
Interest Expense345K420K483K307K90K
Other Income / Expenses(226K)1.1M4.07M3.12M(2.45M)
Income Before Tax(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Pre-Tax Margin——-475.0%-1079.9%—
Income Tax Expense00000
Net Income(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Net Margin——-475.0%-1079.9%—
EPS (Basic)(68.25)(72.00)(93.00)(96.75)(50.83)
EPS (Diluted)(68.25)(72.00)(93.00)(96.75)(50.83)
Weighted Avg Shares607.4K611.71K500.63K536.44K766.6K
Weighted Avg Shares (Diluted)607.4K611.71K500.63K536.44K766.6K

Spruce Biosciences, Inc.

NASDAQ:SPRB

Intrinsic Alpha fair value

Locked

Current Price

$40.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.